Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'
A cross-section of biopharma experts including senior executives of Bayer, Boehringer Ingelheim and Accenture and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.
You may also be interested in...
UK and US regulators explained why some established clinical endpoints are not suitable for use in decentralized trials, and discussed principles to guide the development of novel digital endpoints.
Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.
The US FDA released draft guidance on how device makers, investigators and other stakeholders can use digital health solutions to collect data from clinical study participants remotely. Comments are due to the agency by 22 March 2022.